BCMA/CD3 bispecific T-cell engager
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BCMA/CD3 bispecific T-cell engager, covering 2025-01-10 to 2025-01-10. Get the full timeline:
Most recent: Clinical Trial Update: BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy [NA]